Publications
Detailed Information
Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization in Lipid Keratopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Joo Youn | - |
dc.contributor.author | Kim, Mee Kum | - |
dc.contributor.author | Wee, Won Ryang | - |
dc.date.accessioned | 2023-04-26T08:08:50Z | - |
dc.date.available | 2023-04-26T08:08:50Z | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.created | 2023-04-26 | - |
dc.date.issued | 2009-10 | - |
dc.identifier.citation | Cornea, Vol.28 No.9, pp.1070-1073 | - |
dc.identifier.issn | 0277-3740 | - |
dc.identifier.uri | https://hdl.handle.net/10371/191678 | - |
dc.description.abstract | Purpose: The purpose of this study was to evaluate the efficacy and safety of subconjunctival and corneal intrastromal bevacizumab injections on corneal neovascularization in patients with lipid keratopathy. Methods: Three eyes of 3 patients with lipid keratopathy accompanied by corneal neovascularization received at least 2 subconjunctival and corneal intrastromal injections of bevacizumab (1.25 mg/0.05 mL, respectively) at 1-month intervals. Ophthalmic examinations, including visual acuity, tonometry; slit lamp biomicroscopy, and corneal topography, were performed before injection and every month thereafter. Results: All patients had marked regression of corneal neovascularization. Reduction in lipid deposition was noted in one patient. There were no adverse ocular or systemic events, except for a small intracorneal hemorrhage noted in one patient, which quickly and spontaneously cleared. Conclusion: Subconjunctival and intracorneal bevacizumab is a well-tolerated and effective method for obliterating corneal neovascularization in lipid keratopathy. | - |
dc.language | 영어 | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Subconjunctival and Intracorneal Bevacizumab Injection for Corneal Neovascularization in Lipid Keratopathy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1097/ICO.0b013e31819839f9 | - |
dc.citation.journaltitle | Cornea | - |
dc.identifier.wosid | 000271118400023 | - |
dc.identifier.scopusid | 2-s2.0-70349748824 | - |
dc.citation.endpage | 1073 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 1070 | - |
dc.citation.volume | 28 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Oh, Joo Youn | - |
dc.contributor.affiliatedAuthor | Kim, Mee Kum | - |
dc.contributor.affiliatedAuthor | Wee, Won Ryang | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | AVASTIN | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | VESSELS | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | bevacizumab | - |
dc.subject.keywordAuthor | cornea | - |
dc.subject.keywordAuthor | lipid keratopathy | - |
dc.subject.keywordAuthor | neovascularization | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.